Antibody Ingredients TRIZ Cases

Subcutaneous high affinity IGF-1R antibodies treat thyroid eye disease while avoiding intravenous administration costs and inconvenience.

N10 linker attachment of pyrrolobenzodiazepine dimers to cysteine-modified antibodies resolves the trade-off between high drug loading and off-target toxicity.

Engineered human antibodies target Tn and sTn antigens, resolving antibody generation complexity.

A bispecific antibody bridges HER2 tumor cells and 4-1BB receptors to activate T cells.

Combining ulocuplumab with expanded NK cells disrupts metastatic homing pathways and overcomes drug resistance in pediatric sarcomas.

Engineered monoclonal antibodies block CD40 signaling to treat autoimmune disease.

Modified anti-PD-1 antibodies resolve insufficient T cell activation by boosting cytokine secretion for cancer treatment.

Segmented benzodiazepine dimers expand the therapeutic window by reducing toxicity while maintaining potent anti-tumor activity.

Optimized humanized CD3 antibody frameworks eliminate HAMA responses while maintaining high affinity binding.

Chimeric bispecific antibody targeting CDH3 and CD3 enables cross-species preclinical testing, eliminating separate molecule development.

Defined VH and VL sequences in antigen binding fragments enhance stability and half-life, resolving manufacturing bottlenecks in bispecific antibody production.

A bispecific antigen binding molecule combines OX40 and EpCAM targeting domains to trigger localized immune activation.

Anti-IL-6 receptor antibodies block NF-κB activation in Kupffer cells, resolving the contradiction between general treatment and specific metastasis inhibition.

IgG2 isotype anti-MET antibodies resolve insufficient therapeutic efficacy by enhancing complement-dependent cytotoxicity to control tumor growth.

Bispecific antibodies targeting CD38 and CD47 enhance effector cell redirection to treat multiple myeloma with reduced toxicity.

Anti-LAG-3 antibody therapy addresses limited efficacy in relapsed or refractory cases by targeting LAG-3 expression on tumor-infiltrating lymphocytes.

A bispecific antibody molecule simultaneously binds human MerTK and PD-L1 to deliver dual-targeted therapeutic effects.

Measuring soluble C-terminal adiponectin receptor fragments resolves weak indicator reliability by quantifying disease progression markers.

Bispecific antibody bridges CLL-1 leukemia cells and CD3 T cells to activate cytotoxic killing against resistant acute myeloid leukemia.

Hydrophobic interaction chromatography separates multispecific CrossMab antibodies from mispaired variants using specific resin media.

Engineered interleukin-21 muteins fused to PD-1 antibodies deliver targeted cytokine signaling to expand T cells while minimizing systemic toxicity.

NK cells combined with a bispecific binding protein targeting CD123 and NKp46 eliminate leukemia cells without triggering graft-versus-host disease.

Specific VH and VL CDR sequences enable CD47 antibodies to block SIRP alpha interaction without triggering platelet aggregation or hemagglutination.

Mass spectrometry detects monoclonal antibodies using unique variable region peptides and a horse IgG internal standard for precise concentration measurement.

Intrathecal anti-B7H3 antibodies bypass the blood-brain barrier to deliver cytotoxic agents directly to leptomeningeal carcinomatosis, improving survival rates.

Anti-OSMRβ antibody targets oncostatin M receptor beta to suppress IL-13 levels and skin lesions, addressing ineffective steroid treatments.

Bispecific antibodies bridge OX40 receptors with tumor antigens to localize immune activation at the cancer site, preventing systemic toxicity.

A tri-specific antibody merges tumour targeting with immune checkpoint blockade to redirect T cells.

Segmenting the C5 protein allows an antibody to inhibit C5a-mediated inflammation without blocking MAC assembly, reducing infection risk.

Afucosylated antibodies block TIGIT ligand binding to enhance T cell activation and cytokine production in melanoma treatment.

Bispecific binding proteins redirect NK cells to lyse CD123-expressing tumor cells via Fc receptor engagement.

A CD112 antibody binds to target proteins and blocks receptor interactions.

Antigen binding proteins agonize GITR to enhance effector T cell activity while reducing regulatory T cell suppression.

A CAPRIN-1 targeting antibody delivers antitumor activity through specific surface recognition.

Removing the PAB group from the linker structure enhances ADC hydrophilicity and antibody affinity while maintaining tumor cell cleavage capability.

Asymmetric bivalent Fab constructs eliminate Fc-mediated cytokine release and toxicity while maintaining high specificity for peptide-MHC complexes.

Removing CH2 glycans and adding L234A substitutions blocks FcγR interaction to prevent neutropenia while relieving immunosuppression.

Bispecific antibodies co-cluster the inhibitory G6b-B receptor with activating ITAM receptors to block platelet signaling pathways.

Humanized monoclonal antibodies bind human CD40 with modified Fc regions to enhance specificity for the inhibitory receptor FcγRIIb.

HBBK4 overcomes cancer immune evasion by activating 4-1BB receptors to boost CD8+ T cell infiltration and IFN-γ production.

E-selectin inhibitors prevent leukocyte adhesion to resolve G-CSF-induced vascular complications.

A bispecific antibody binds EGFR and 4-1BB to activate immune signaling at tumor sites.

Trifunctional bispecific antibodies bridge tumor antigens and T cells via Fcγ-receptors, destroying low-expression tumors.

High-affinity anti-Trop-2 monoclonal antibodies target specific tumor epitopes, reducing systemic toxicity while maintaining strong anti-tumor activity.

Peptides extracted from monoclonal antibody CDR3 regions correct dendritic cell functional bias to inhibit tumor growth while avoiding immune system impairment.

Lipid nanoparticles deliver RNA encoding Claudin-18.2-targeting antibodies to liver cells for in vivo production.

Using isolated IgG to detect binding with galactose-deficient IgA1 overcomes complexity of aberrantly glycosylated IgA1.

Adding IL-12 to differentiation media boosts CD62L, CD16, and chemokine receptors, resolving insufficient migration and cytotoxicity in NK cell therapies.

A multispecific antibody binds tumor antigens and immune checkpoints to reduce systemic toxicities.